{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:50:08Z","timestamp":1769223008886,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Diabetes Wellington, New Zealand"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,5]]},"abstract":"\n Aims<\/jats:title>\n To determine whether an individualized body weight\u2010based glucose treatment in adults with type 2 diabetes (T2DM) is more likely to resolve hypoglycaemia with a single treatment without excessive rebound hyperglycaemia compared to fixed doses of 12 or 30 g of glucose.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Adults with T2DM were enrolled in a cross\u2010over study. Each episode of hypoglycaemia (capillary glucose <4.0 mmol\/L) was randomly assigned to 1 of 3 treatment protocols: 0.3 g glucose\/kg body\u2010weight or a fixed dose of either 12 or 30 g glucose, independent of weight. All participants received each treatment in random order for up to 15 hypoglycaemic episodes. Glucose was re\u2010tested 10 minutes after treatment, with a repeat dose if still <4 mmol\/L.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Mean (SD) age of the 30 participants was 68 (8.1) years, mean weight was 91.5 (16.8) kg and mean HbA1c was 58.7 (9.2) mmol\/mol. Among a total of 244 episodes of hypoglycaemia, 10 participants had 15 treatment episodes and 18 participants had fewer than 10 treatment episodes. The odds ratio, adjusted for multiple comparisons, for resolution of hypoglycaemia at 10 minutes, comparing weight\u2010based treatment and 12 g treatment was 3.2 (95% CI, 1.1\u20139.0),\n P<\/jats:italic>\n = .009, comparing 30 g treatment and 12 g treatment was 8.9 (95% CI, 2.2\u201336.6),\n P<\/jats:italic>\n < .001, and comparing weight\u2010based treatment and 30 g treatment was 0.36 (95% CI, 0.08\u20131.67)\n P<\/jats:italic>\n = .10.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In T2DM, both a weight\u2010based 0.3 g\/kg treatment and a fixed 30 g glucose treatment result in higher blood glucose than a 12 g treatment, along with increased probability of resolution of hypoglycaemia after 10 minutes. Both treatments result in an excess of mild rebound hyperglycaemia (>8 mmol\/L) at 30 minutes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.13231","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T07:46:49Z","timestamp":1516693609000},"page":"1256-1261","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing the management of hypoglycaemia in individuals with type 2 diabetes: A randomized crossover comparison of a weight\u2010based protocol compared with two fixed\u2010dose glucose regimens"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-3447","authenticated-orcid":false,"given":"Jeremy D.","family":"Krebs","sequence":"first","affiliation":[{"name":"Department of Medicine University of Otago Wellington Wellington New Zealand"},{"name":"Centre for Endocrine, Diabetes and Obesity Research (CEDOR) Capital and Coast District Health Board Wellington New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago Wellington Wellington New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Corley","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago Wellington Wellington New Zealand"},{"name":"Centre for Endocrine, Diabetes and Obesity Research (CEDOR) Capital and Coast District Health Board Wellington New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esko","family":"Wiltshire","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health University of Otago Wellington Wellington New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"McTavish","sequence":"additional","affiliation":[{"name":"Centre for Endocrine, Diabetes and Obesity Research (CEDOR) Capital and Coast District Health Board Wellington New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.09.001"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01501.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S009"},{"key":"e_1_2_6_6_1","unstructured":"National Institute for Health and Care Excellence.Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17];2015. Available athttps:\/\/www.nice.org.uk\/guidance\/ng17. Accessed December 1 2017."},{"issue":"1","key":"e_1_2_6_7_1","first-page":"S69","article-title":"Hypoglycemia","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert C","year":"2013","journal-title":"Can J Diabetes"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.12.2948"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2009.00558.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.150.3.589"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12730"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2010.00725.x"},{"key":"e_1_2_6_13_1","article-title":"Weight\u2010based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial","author":"McTavish L","year":"2017","journal-title":"Diabet Med"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.1.202"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:39Z","timestamp":1761870339000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/dom.13231"],"URL":"https:\/\/doi.org\/10.1111\/dom.13231","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}